Tess Burleson - Jan 3, 2023 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Director
Signature
/s/ David J. Arthur, Attorney-in-Fact
Stock symbol
SLRX
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/5/2023, 04:47 PM
Previous filing
Jun 8, 2022
Next filing
Feb 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $0 +1.44K +112.32% $0.00 2.72K Jan 3, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024